Combination therapy with sotatercept analog RAP-011 is superior to sildenafil alone in severe experimental PAH and RAP-011 benefits persist after treatment cessation

S. JOSHI (Cambridge, United States of America), J. Liu (Cambridge, United States of America), R. Pearsall (Cambridge, United States of America), P. Andre (Cambridge, United States of America), G. Li (Cambridge, United States of America), R. Kumar (Cambridge, United States of America)

Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension
Session: Updated assessment and treatment of pulmonary arterial hypertension
Session type: Oral Presentation
Number: 3968

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. JOSHI (Cambridge, United States of America), J. Liu (Cambridge, United States of America), R. Pearsall (Cambridge, United States of America), P. Andre (Cambridge, United States of America), G. Li (Cambridge, United States of America), R. Kumar (Cambridge, United States of America). Combination therapy with sotatercept analog RAP-011 is superior to sildenafil alone in severe experimental PAH and RAP-011 benefits persist after treatment cessation. 3968

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: